Transition to Dolutegravir Is Associated With an Increase in the Rate of Body Mass Index Change in a Cohort of Virally Suppressed Adolescents. (29th October 2020)

• Record Type: Journal Article
• Authors: Thivalapill, Neil; Simelane, Tandzile; Mthethwa, Nobuhle; Dlamini, Sandile; Lukhele, Bhekumusa; Okello, Velephi; Kirchner, H Lester; Mandalakas, Anna M; Kay, Alexander W
• Is Part Of: Clinical infectious diseases. Volume 73:Number 3(2021)
• Page Start: e580
• Page End: e586
• Publication Date: 2020-10-29
• Subjects: HIV -- adolescent -- body mass index -- adverse events; Communicable diseases -- Periodicals; 616.905
• DOI: 10.1093/cid/ciaa1652
• Languages: English
• ISSNs: 1058-4838

Abstract

Abstract: Background: Antiretroviral therapy (ART) regimens that contain dolutegravir (DTG) have been associated with increases in body mass index (BMI) in adults. However, this relationship has not been well described in adolescents. Methods: In a retrospective observational cohort of 460 virally suppressed (<200 copies/mL) adolescents living with human immunodeficiency virus at a clinical site in Eswatini, body mass index (BMI) measurements were analyzed between 1 year prior to the transition to DTG and up to 1 year after DTG transition. Random-effects linear spline models were used to describe the rate of change in BMI before and after the transition to DTG. Results: In adolescents, BMI increased at a rate of 0.3 kg/m 2 per year before DTG transition and increased to a rate of 1.2 kg/m 2 per year after DTG transition. Sex of the adolescent modified the relationship between DTG and rate of BMI change: BMI rate of change after DTG transition was increased by 1.1 kg/m 2 in females and 0.6 kg/m 2 per year in males. Conclusions: Transition to DTG in virally suppressed adolescents (aged 10–19 years) is associated with an increase in the rate of BMI change. Female adolescents may experience a larger change than males. Further investigation is required to elucidate the mechanism that underlies these observations and to assess how DTG impacts BMI in adolescents following longer durations of treatment. Abstract : Dolutegravir has been associated with weight gain in adults. In this cohort of virally suppressed adolescents living with Human Immunodeficiency Virus, transition to dolutegravir was associated with an accelerated rate of body mass index increase. The effect was most pronounced in female adolescents.